CN110139852A - 三环杂环衍生物及其用途 - Google Patents

三环杂环衍生物及其用途 Download PDF

Info

Publication number
CN110139852A
CN110139852A CN201780082274.1A CN201780082274A CN110139852A CN 110139852 A CN110139852 A CN 110139852A CN 201780082274 A CN201780082274 A CN 201780082274A CN 110139852 A CN110139852 A CN 110139852A
Authority
CN
China
Prior art keywords
methyl
oxy
alkylene
ethoxy
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780082274.1A
Other languages
English (en)
Chinese (zh)
Inventor
A·J·马歇尔
C·M·布坎南
G·W·鲁卡斯尔
G·路
J·U·弗拉纳根
M·邦内特
P·R·谢泼德
S·M·F·贾米森
S·A·加米奇
W·A·丹尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of CN110139852A publication Critical patent/CN110139852A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D311/86—Oxygen atoms, e.g. xanthones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12—Thioxanthenes
    • C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D335/16—Oxygen atoms, e.g. thioxanthones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12—Thioxanthenes
    • C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D335/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
CN201780082274.1A 2016-11-04 2017-11-03 三环杂环衍生物及其用途 Pending CN110139852A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ72576716 2016-11-04
NZ725767 2016-11-04
PCT/IB2017/056848 WO2018083635A2 (en) 2016-11-04 2017-11-03 Tricyclic heterocyclic derivatives and uses thereof

Publications (1)

Publication Number Publication Date
CN110139852A true CN110139852A (zh) 2019-08-16

Family

ID=62075593

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780082274.1A Pending CN110139852A (zh) 2016-11-04 2017-11-03 三环杂环衍生物及其用途

Country Status (6)

Country Link
US (1) US11028064B2 (enExample)
EP (1) EP3535243B1 (enExample)
JP (1) JP7096817B2 (enExample)
CN (1) CN110139852A (enExample)
AU (1) AU2017355603A1 (enExample)
WO (1) WO2018083635A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110770209A (zh) * 2017-03-13 2020-02-07 光州科学技术院 用作p2x1及p2x3受体拮抗剂的新型5-羟基吡啶类化合物及包含其的药物组合物
CN114890899A (zh) * 2022-04-02 2022-08-12 南京农业大学 一种制备二苯醚酯类化合物的方法
CN115557890A (zh) * 2022-09-01 2023-01-03 宁波大学 一种多取代吖啶酮烷基衍生物及其制备方法和用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108976164A (zh) * 2018-06-20 2018-12-11 南通常佑药业科技有限公司 手性哌啶胺化合物的制备方法及手性拆分剂的回收套用方法
WO2021101521A1 (en) * 2019-11-19 2021-05-27 Provecetus Pharmatech, Inc. Composition and method for treating hematologic cancers
BR112023004719A2 (pt) * 2020-09-21 2023-04-18 Hutchison Medipharma Ltd Compostos heteroaromáticos e usos dos mesmos
IT202200024963A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio Kv7.2/Kv7.3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1192651A (en) * 1968-01-09 1970-05-20 Sterling Drug Inc Xanthene Derivatives
AU3390871A (en) * 1970-12-11 1973-04-05 Richardson-Merrell Inc Bis-basic ketones of xanthene and xanthen 9 one and antiviral compositions thereof
US20110065712A1 (en) * 2009-09-16 2011-03-17 Cylene Pharmaceuticals , Inc. Tricyclic compounds and pharmaceutical uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759292A (fr) 1969-11-27 1971-05-24 Allen & Hanburys Ltd Derives de xanthone, leur preparation et leur emploi
EP0278176B1 (en) 1986-12-23 1994-03-09 Warner-Lambert Company Compounds having antitumour and antibacterial properties
AU2002367773A1 (en) 2001-04-06 2003-11-03 Affinium Pharmaceuticals, Inc. Fab i inhibitors
JP4654035B2 (ja) 2002-11-05 2011-03-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗菌剤
WO2005003131A1 (en) 2003-06-27 2005-01-13 Janssen Pharmaceutica N.V. Tricyclic delta opioid modulators
AU2005335481A1 (en) 2004-08-05 2007-04-19 Janssen Pharmaceutica N.V. Tricyclic delta- opioid modulators
WO2006044707A1 (en) 2004-10-13 2006-04-27 Smithkline Beecham Corporation Chemical compounds
PE20080359A1 (es) 2006-04-19 2008-06-06 Novartis Ag Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r
WO2008016661A2 (en) * 2006-08-02 2008-02-07 Xanthus Pharmaceuticals, Inc. Morpholino compounds for treating inflammatory and demyelinating diseases and cancers
WO2008048117A2 (en) 2006-10-17 2008-04-24 Auckland Uniservices Limited Synthesis of 5,6-dimethyl-9-oxo-9h-xanthen-4-yl- acetic acid (dmxaa)
AU2007309279B2 (en) 2006-10-20 2011-03-24 Irm Llc Compositions and methods for modulating c-kit and PDGFR receptors
CN101195609B (zh) 2007-09-28 2011-04-20 武汉远大制药集团有限公司 5,6-二甲基呫吨酮-4-乙酸的制备方法及由此方法制备的衍生物和药物制剂
DE102007047495B4 (de) 2007-10-04 2009-07-16 Contitech Kühner Gmbh & Cie. Kg Wellrohrschlauchleitung sowie Verfahren zu deren Herstellung
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
CN101279967B (zh) 2008-05-29 2010-11-10 武汉远大制药集团有限公司 一种治疗癌症的三甲基呫吨酮-4-乙酸药物组合物及其用途
AR072295A1 (es) 2008-06-26 2010-08-18 Novartis Ag Metodo de preparacion del acio 5,6-dimetil-9-oxo-9h-xanten-4-il-acetico
US20110201678A1 (en) 2008-10-17 2011-08-18 Masse Craig E Xanthenone-4-Acetic Acid Derivatives
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
UA108222C2 (xx) 2009-12-21 2015-04-10 СПОЛУКИ ЗАМІЩЕНОГО N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗОЛ$1,2-а]ПІРИДИН-3-КАРБОКСАМІДУ ЯК ІНГІБІТОРИ cFMS
TWI414520B (zh) 2010-10-06 2013-11-11 Nat Defense Medical Ct 噻噸酮衍生物
PH12013501221A1 (en) 2010-12-13 2022-03-30 Array Biopharma Inc SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
NO2694640T3 (enExample) 2011-04-15 2018-03-17
EP2791143B1 (en) 2011-12-15 2016-02-24 Bayer Intellectual Property GmbH Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment of cancer
GB2498976A (en) 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2842937B1 (en) 2012-04-23 2018-01-17 Mitsubishi Tanabe Pharma Corporation Amine compound and use thereof for medical purposes
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1192651A (en) * 1968-01-09 1970-05-20 Sterling Drug Inc Xanthene Derivatives
AU3390871A (en) * 1970-12-11 1973-04-05 Richardson-Merrell Inc Bis-basic ketones of xanthene and xanthen 9 one and antiviral compositions thereof
US20110065712A1 (en) * 2009-09-16 2011-03-17 Cylene Pharmaceuticals , Inc. Tricyclic compounds and pharmaceutical uses thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110770209A (zh) * 2017-03-13 2020-02-07 光州科学技术院 用作p2x1及p2x3受体拮抗剂的新型5-羟基吡啶类化合物及包含其的药物组合物
CN110770209B (zh) * 2017-03-13 2023-06-30 光州科学技术院 用作p2x1及p2x3受体拮抗剂的新型5-羟基吡啶类化合物及包含其的药物组合物
CN114890899A (zh) * 2022-04-02 2022-08-12 南京农业大学 一种制备二苯醚酯类化合物的方法
CN114890899B (zh) * 2022-04-02 2023-10-03 南京农业大学 一种制备二苯醚酯类化合物的方法
CN115557890A (zh) * 2022-09-01 2023-01-03 宁波大学 一种多取代吖啶酮烷基衍生物及其制备方法和用途

Also Published As

Publication number Publication date
EP3535243A4 (en) 2020-05-06
JP2019537602A (ja) 2019-12-26
EP3535243B1 (en) 2021-12-15
WO2018083635A2 (en) 2018-05-11
AU2017355603A1 (en) 2019-06-20
EP3535243A2 (en) 2019-09-11
US11028064B2 (en) 2021-06-08
WO2018083635A3 (en) 2018-07-26
JP7096817B2 (ja) 2022-07-06
US20190276423A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
US11530218B2 (en) Spiro compounds as inhibitors of KRAS
JP7753246B2 (ja) 融合三環式ｋｒａｓ阻害剤
CN110139852A (zh) 三环杂环衍生物及其用途
US12030883B2 (en) Hetero-tricyclic compounds as inhibitors of KRAS
KR20200133747A (ko) 암을 치료하기 위한 hpk1 억제제로서의 n-(페닐)-2-(페닐)피리미딘-4-카복스아미드 유도체 및 관련 화합물
TWI538913B (zh) 嘌呤衍生物
JP2024529347A (ja) Ｋｒａｓの阻害剤としての三環式化合物
CN102947272A (zh) 用作atr激酶抑制剂的2-氨基吡啶衍生物
AU2021289169B2 (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
TWI784213B (zh) 雜環化合物
JP2012507512A (ja) アミロイドβのモジュレーター
BR112020019111A2 (pt) Derivados de imidazolidin-2-ona substituída como inibidores de prmt5
JP2022500428A (ja) 毛細血管拡張性運動失調症変異（ＡＴＭ）キナーゼの選択的調節物質としての１−イソプロピル−３−メチル−８−（ピリジン−３−イル）−１，３−ジヒドロ−２Ｈ−イミダゾ［４，５−ｃ］シンノリン−２−オンおよびその使用
JP2020525471A (ja) Ｎｉｋ阻害剤としての新規の置換アザインドリン誘導体
AU2024240851A1 (en) Triazine compound and use thereof
US20250171447A1 (en) Adenosine receptor antagonists, pharmaceutical compositions and their use thereof
RU2813541C1 (ru) Спиросоединения в качестве антагонистов рецепторов меланокортина 4 и их применения
EA048766B1 (ru) Конденсированные трициклические ингибиторы kras
HK40074236A (en) Covalent ras inhibitors and uses thereof
HK40087858B (zh) 作为黑皮质素4受体拮抗剂的螺环化合物及其用途
HK40087858A (zh) 作为黑皮质素4受体拮抗剂的螺环化合物及其用途
HK40051951B (zh) 杂环化合物
HK1240917A1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
HK1181050A (en) 2-aminopyridine derivatives useful as inhibitors of atr kinase

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination